ContributorsPublishersAdvertisers

Castle Biosciences test improves accuracy of risk prediction in skin cancer: study

Seeking Alpha
Seeking Alpha
 2022-01-14
Cover picture for the article

Castle Biosciences (NASDAQ:CSTL) said a study showed DecisionDx-SCC provides significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors...

seekingalpha.com

Comments / 0

Comments / 0